A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Prior treatment

• Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization

Other illness

• History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody
• History of allergy or hypersensitivity to any of the chemotherapeutics or any of their excipients
• Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma, symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases

Lab values

• Any prior or current clinical diagnosis of heart failure, irrespective of left ventricular ejection fraction or New York Heart Association classification
• Left ventricular ejection fraction \<50%
• Renal disease requiring dialysis or eGFR \<30 mL/min/1.73m2

Other

• Current active reversible causes of decreased food intake
• Cachexia caused by other reasons
• Inadequate liver function

• Signed Informed Consent Document
• Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma
• Cachexia defined by Fearon criteria of weight loss
• Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and prior to receiving Cycle 2 chemotherapy
• ECOG PS ≤1 with life expectancy of at least 4 months